摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-methylbenzyl)hydrazine dihydrochloride | 26177-51-5

中文名称
——
中文别名
——
英文名称
(4-methylbenzyl)hydrazine dihydrochloride
英文别名
(4-methyl-benzyl)-hydrazine; hydrochloride;(4-Methyl-benzyl)-hydrazin; Hydrochlorid
(4-methylbenzyl)hydrazine dihydrochloride化学式
CAS
26177-51-5
化学式
C8H13ClN2
mdl
——
分子量
172.65
InChiKey
FZDQALMNASCCIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    158-160 °C

计算性质

  • 辛醇/水分配系数(LogP):
    1.38
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    39.7
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2928000090

SDS

SDS:0dd4c5052906ca4dc1fd9ab642f555b3
查看

反应信息

点击查看最新优质反应信息

文献信息

  • <i>N</i> ‐Amino‐1,8‐Naphthalimide is a Regenerated Protecting Group for Selective Synthesis of Mono‐N‐Substituted Hydrazines and Hydrazides
    作者:Mesram Manoj Kumar、Parikibanda Venkataramana、Parikibanda Yadagiri Swamy、Yadaiah Chityala
    DOI:10.1002/chem.202102593
    日期:2021.12.15
    N-Amino-1,8-naphthalimide was used as a protecting group and a reagent to selective synthesis of various mono-N-substituted hydrazines and hydrazides. In all these reactions, the protecting reagent N-amino-1,8-naphthalimide was easily regenerated in good yields by the hydrazinolysis. All these transformations showed good functional-group tolerance and can be used for large scale C−N cross-coupling
    N-基-1,8-二甲酰亚胺用作保护基团和试剂,用于选择性合成各种单-N-取代的和酰。在所有这些反应中,保护试剂N-基-1,8-二甲酰亚胺很容易通过解以良好的产率再生。所有这些转化都显示出良好的官能团耐受性,可用于大规模的 CN 交叉偶联反应。
  • PHARMACEUTICAL COMPOSITIONS
    申请人:LAZZARI Paolo
    公开号:US20100216785A1
    公开(公告)日:2010-08-26
    Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, O) from 0.01 to 95% of one or more oils selected from esters of C 4 -C 32 acids or C 4 -C 32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A′: AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.
    药物组成的微乳液包含以下组分(按重量百分比计算),各组分总和为100%:S)从0.01到95%的一种或多种化合物,选自表面活性剂、聚合物,形成有序结构,如:聚集体、胶束、液晶、囊泡,在它们被溶解的液体中,O)从0.01到95%的一种或多种油,选自C4-C32酸酯或C4-C32酸,PA)从0.001到90%的化合物,具有亲和力为公式A'的CB1和/或CB2大麻素受体,AD)从0到60%的一种或多种化合物,按重量计算,选自调节剂,和/或油极性的调节剂,组分S)的膜曲率调节剂,共表面活性剂,或盐溶液之差为100%,其中按重量比S)/PA)低于不含组分O)的微乳液的比例。
  • Tricyclic condensed pyrazole derivatives as CB1 inhibitors
    申请人:Neuroscienze Pharmaness S.C. A R.L.
    公开号:EP2223914A1
    公开(公告)日:2010-09-01
    Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I) : wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
    具有紧凑结构的三环化合物,其中包含一个苯环和一个吡唑环,通过一个含有五至八个原子的中心环相互连接,具有对CB1和/或CB2受体的亲和力,具有中枢神经系统和/或外周活性,化学式为(I):其中各种取代基如描述中定义。这些化合物显示对CB1和/或CB2大麻素受体的亲和力。
  • PHARMACEUTICAL COMPOUNDS
    申请人:LAZZARI Paolo
    公开号:US20100215741A1
    公开(公告)日:2010-08-26
    Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
    具有紧凑结构的三环化合物,包含一个苯环和一个吡唑环,通过一个由五至八个原子组成的中心环相互连接,在CB1和/或CB2受体上具有亲和力,具有中枢神经系统和/或外周活性,化学式(I)如下:其中各种取代基如描述中所定义。这些化合物对CB1和/或CB2类大麻素受体具有亲和力。
  • Pharmaceutical compounds
    申请人:Neuroscienze Pharmaness S.C. A R.L.
    公开号:EP2230243A1
    公开(公告)日:2010-09-22
    Condensed tricyclic pyrazole compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors, with activity both on the peripheral and central nervous system, of formula (I) : wherein: A represents a group selected from -(CH2)t-, -(CH2)r-O-(CH2)s- and -(CH2)r-S(O)p-(CH2)s- B is an heteroaryl, R is a group selected from heteroaryl, heteroarylalkyl, aryl, arylalkyl, arylalkenyl or bivalent aliphatic chain, R' is a group selected from the following: R'1: a substituent bearing a keto group of formula -C(O)-(Z')v-Z" R'2: a substituent having an hydroxylic function of formula -CH(OH)-(Z')v-Z", R'3: an amide substituent of formula -C(O)-NH-(Z')v-T'.
    具有对CB1和/或CB2大麻素受体亲和力的紧凑三环吡唑化合物,对外周和中枢神经系统均具有活性,其化学式为(I):其中:A代表从-(CH2)t-, -( )r-O-( )s-和-( )r-S(O)p-( )s-B中选择的基团,B是杂芳基,R是从杂芳基、杂芳烷基、芳基、芳基烷基、芳基烯基或二价脂肪链中选择的基团,R'是从以下选择的基团:R'1:具有化学式-C(O)-(Z')v-Z"的酮基团的取代基,R'2:具有化学式-CH(OH)-(Z')v-Z"的羟基功能的取代基,R'3:具有化学式-C(O)-NH-(Z')v-T'的酰胺取代基。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫